CIK 0001840233 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Xilio Therapeutics, Inc.
Sign in to watch- Ticker
- XLO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 851623397
- Phone
- 617-833-1027
- Business address
- 828 WINTER STREET, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 8 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-08-16 | Russo Rene CEO | Grant or award · Stock Option (right to buy) | +700,000 | 700,000 | ||
| 2023-08-16 | Frankenfield Christopher James CHIEF OPERATING OFFICER | Grant or award · Stock Option (right to buy) | +300,000 | 300,000 | ||
| 2023-08-16 | Brennan Kevin M. SVP, FINANCE AND ACCOUNTING | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2023-08-16 | Huber Martin H. Jr. PRESIDENT AND HEAD OF R&D | Grant or award · Stock Option (right to buy) | +136,500 | 136,500 | ||
| 2023-08-03 | Frankenfield Christopher James Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +150,000 | 150,000 | ||
| 2023-06-12 | Xu Yuan Director | Grant or award · Stock Option (right to buy) | +13,200 | 13,200 | ||
| 2023-06-12 | ROSS ROBERT W. Director | Grant or award · Stock Option (right to buy) | +13,200 | 13,200 | ||
| 2023-06-12 | Heyman Tomas J. Director | Grant or award · Stock Option (right to buy) | +13,200 | 13,200 | ||
| 2023-06-12 | Bonstein Sara Director | Grant or award · Stock Option (right to buy) | +13,200 | 13,200 | ||
| 2023-06-12 | Clancy Paul J Director | Grant or award · Stock Option (right to buy) | +13,200 | 13,200 | ||
| 2023-06-12 | Rossi Christina Director | Grant or award · Stock Option (right to buy) | +13,200 | 13,200 | ||
| 2023-04-01 | Brennan Kevin M. SVP, FINANCE AND ACCOUNTING | Grant or award · Stock Option (right to buy) | +55,000 | 55,000 | ||
| 2023-01-01 | Russo Rene CEO | Grant or award · Stock Option (right to buy) | +350,000 | 350,000 | ||
| 2023-01-01 | Huber Martin H. Jr. PRESIDENT AND HEAD OF R&D | Grant or award · Stock Option (right to buy) | +136,500 | 136,500 | ||
| 2023-01-01 | English Edward C PRINCIPAL ACCOUNTING OFFICER | Grant or award · Stock Option (right to buy) | +24,000 | 24,000 | ||
| 2022-09-15 | Heyman Tomas J. Director | Grant or award · Stock Option (right to buy) | +26,400 | 26,400 | ||
| 2022-06-15 | Huber Martin H. Jr. PRESIDENT AND HEAD OF R&D | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2022-06-15 | Huber Martin H. Jr. PRESIDENT AND HEAD OF R&D | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2022-06-15 | Ross Michael Jay Director | Grant or award · Stock Option (right to buy) | +13,200 | 13,200 | ||
| 2022-06-15 | Rossi Christina Director | Grant or award · Stock Option (right to buy) | +13,200 | 13,200 |
Page 8 of 12 · 224 trades